Canonical Wnt signaling is essential for a plethora of biological processes ranging from early embryogenesis to aging. Malfunctions of this crucial signaling pathway are associated with various developmental defects and diseases, including cancer. Although TCF/LEF transcription factors (TCF/LEFs) are known to be essential for this pathway, the regulation of their intracellular levels is not completely understood. Here, we show that the lysine demethylase KDM2A promotes the proteasomal destabilization of TCF/LEFs independently of its demethylase domain. We found that the KDM2A-mediated destabilization of TCF/LEFs is dependent on the KDM2A zinc finger CXXC domain. Furthermore, we identified the C-terminal region of TCF7L2 and the CXXC domain of KDM2A as the domains responsible for the interaction between the two proteins. Our study is also the first to show that endogenous TCF/LEF proteins undergo KDM2A-mediated proteasomal degradation in a neddylation-dependent manner. Here, we reveal a completely new mechanism that affects canonical Wnt signaling by regulating the levels of TCF/LEF transcription factors through their KDM2A-promoted proteasomal degradation.

Institute of Biology and Medical Genetics 1st Faculty of Medicine Charles University and General University Hospital Prague 128 01 Prague Czech Republic

Institute of Histology and Embryology 1st Faculty of Medicine Charles University and General University Hospital Prague 128 01 Prague Czech Republic

Zobrazit více v PubMed

Nusse R., Clevers H. Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell. 2017;169:985–999. doi: 10.1016/j.cell.2017.05.016. PubMed DOI

Anastas J.N., Moon R.T. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer. 2013;13:11–26. doi: 10.1038/nrc3419. PubMed DOI

Clevers H., Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149:1192–1205. doi: 10.1016/j.cell.2012.05.012. PubMed DOI

Sokol S.Y. Maintaining embryonic stem cell pluripotency with Wnt signaling. Development. 2011;138:4341–4350. doi: 10.1242/dev.066209. PubMed DOI PMC

Cadigan K.M., Peifer M. Wnt signaling from development to disease: Insights from model systems. Cold Spring Harb. Perspect. Biol. 2009;1:a002881. doi: 10.1101/cshperspect.a002881. PubMed DOI PMC

Liu C., Li Y., Semenov M., Han C., Baeg G.H., Tan Y., Zhang Z., Lin X., He X. Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002;108:837–847. doi: 10.1016/S0092-8674(02)00685-2. PubMed DOI

Shen C., Wang D., Liu X., Gu B., Du Y., Wei F.Z., Cao L.L., Song B., Lu X., Yang Q., et al. SET7/9 regulates cancer cell proliferation by influencing β-catenin stability. FASEB J. 2015;29:4313–4323. doi: 10.1096/fj.15-273540. PubMed DOI

Lu L., Gao Y., Zhang Z., Cao Q., Zhang X., Zou J., Cao Y. Kdm2a/b Lysine Demethylases Regulate Canonical Wnt Signaling by Modulating the Stability of Nuclear β-Catenin. Dev. Cell. 2015;33:660–674. doi: 10.1016/j.devcel.2015.04.006. PubMed DOI

Gao C., Xiao G., Hu J. Regulation of Wnt/beta-catenin signaling by posttranslational modifications. Cell Biosci. 2014;4:13. doi: 10.1186/2045-3701-4-13. PubMed DOI PMC

Gay F., Calvo D., Lo M.C., Ceron J., Maduro M., Lin R., Shi Y. Acetylation regulates subcellular localization of the Wnt signaling nuclear effector POP-1. Genes Dev. 2003;17:717–722. doi: 10.1101/gad.1042403. PubMed DOI PMC

Hikasa H., Ezan J., Itoh K., Li X., Klymkowsky M.W., Sokol S.Y. Regulation of TCF3 by Wnt-dependent phosphorylation during vertebrate axis specification. Dev. Cell. 2010;19:521–532. doi: 10.1016/j.devcel.2010.09.005. PubMed DOI PMC

Hikasa H., Sokol S.Y. Phosphorylation of TCF proteins by homeodomain-interacting protein kinase 2. J. Biol. Chem. 2011;286:12093–12100. doi: 10.1074/jbc.M110.185280. PubMed DOI PMC

Ishitani T., Ninomiya-Tsuji J., Nagai S., Nishita M., Meneghini M., Barker N., Waterman M., Bowerman B., Clevers H., Shibuya H., et al. The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature. 1999;399:798–802. doi: 10.1038/21674. PubMed DOI

Vacik T., Ladinovic D., Raska I. KDM2A/B lysine demethylases and their alternative isoforms in development and disease. Nucleus. 2018;9:431–441. doi: 10.1080/19491034.2018.1498707. PubMed DOI PMC

Tsukada Y., Fang J., Erdjument-Bromage H., Warren M.E., Borchers C.H., Tempst P., Zhang Y. Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2006;439:811–816. doi: 10.1038/nature04433. PubMed DOI

Liu L., Liu J., Lin Q. Histone demethylase KDM2A: Biological functions and clinical values (Review) Exp. Ther. Med. 2021;22:723. doi: 10.3892/etm.2021.10155. PubMed DOI PMC

Dhar S.S., Alam H., Li N., Wagner K.W., Chung J., Ahn Y.W., Lee M.G. Transcriptional repression of histone deacetylase 3 by the histone demethylase KDM2A is coupled to tumorigenicity of lung cancer cells. J. Biol. Chem. 2014;289:7483–7496. doi: 10.1074/jbc.M113.521625. PubMed DOI PMC

Wagner K.W., Alam H., Dhar S.S., Giri U., Li N., Wei Y., Giri D., Cascone T., Kim J.H., Ye Y., et al. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. J. Clin. Investig. 2013;123:5231–5246. doi: 10.1172/JCI68642. PubMed DOI PMC

Kooistra S.M., Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat. Rev. Mol. Cell Biol. 2012;13:297–311. doi: 10.1038/nrm3327. PubMed DOI

Blackledge N.P., Zhou J.C., Tolstorukov M.Y., Farcas A.M., Park P.J., Klose R.J. CpG islands recruit a histone H3 lysine 36 demethylase. Mol. Cell. 2010;38:179–190. doi: 10.1016/j.molcel.2010.04.009. PubMed DOI PMC

Lu T., Jackson M.W., Wang B., Yang M., Chance M.R., Miyagi M., Gudkov A.V., Stark G.R. Regulation of NF-κB by NSD1/FBXL11-dependent reversible lysine methylation of p65. Proc. Natl. Acad. Sci. USA. 2010;107:46–51. doi: 10.1073/pnas.0912493107. PubMed DOI PMC

Borgel J., Tyl M., Schiller K., Pusztai Z., Dooley C.M., Deng W., Wooding C., White R.J., Warnecke T., Leonhardt H., et al. KDM2A integrates DNA and histone modification signals through a CXXC/PHD module and direct interaction with HP1. Nucleic Acids Res. 2017;45:1114–1129. doi: 10.1093/nar/gkw979. PubMed DOI PMC

Ladinovic D., Novotna J., Jaksova S., Raska I., Vacik T. A demethylation deficient isoform of the lysine demethylase KDM2A interacts with pericentromeric heterochromatin in an HP1a-dependent manner. Nucleus. 2017;8:563–572. doi: 10.1080/19491034.2017.1342915. PubMed DOI PMC

Frescas D., Guardavaccaro D., Kuchay S.M., Kato H., Poleshko A., Basrur V., Elenitoba-Johnson K.S., Katz R.A., Pagano M. KDM2A represses transcription of centromeric satellite repeats and maintains the heterochromatic state. Cell Cycle. 2008;7:3539–3547. doi: 10.4161/cc.7.22.7062. PubMed DOI PMC

Bueno M.T.D., Baldascini M., Richard S., Lowndes N.F. Recruitment of lysine demethylase 2A to DNA double strand breaks and its interaction with 53BP1 ensures genome stability. Oncotarget. 2018;9:15915–15930. doi: 10.18632/oncotarget.24636. PubMed DOI PMC

Liu X., Li J., Wang Z., Meng J., Wang A., Zhao X., Xu Q., Cai Z., Hu Z. KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells. Front. Oncol. 2021;11:653788. doi: 10.3389/fonc.2021.653788. PubMed DOI PMC

Gorelik M., Manczyk N., Pavlenco A., Kurinov I., Sidhu S.S., Sicheri F. A Structure-Based Strategy for Engineering Selective Ubiquitin Variant Inhibitors of Skp1-Cul1-F-Box Ubiquitin Ligases. Structure. 2018;26:1226–1236.e3. doi: 10.1016/j.str.2018.06.004. PubMed DOI PMC

Zhang H., Rong X., Wang C., Liu Y., Lu L., Li Y., Zhao C., Zhou J. VBP1 modulates Wnt/β-catenin signaling by mediating the stability of the transcription factors TCF/LEFs. J. Biol. Chem. 2020;295:16826–16839. doi: 10.1074/jbc.RA120.015282. PubMed DOI PMC

Yamada M., Ohnishi J., Ohkawara B., Iemura S., Satoh K., Hyodo-Miura J., Kawachi K., Natsume T., Shibuya H. NARF, an nemo-like kinase (NLK)-associated ring finger protein regulates the ubiquitylation and degradation of T cell factor/lymphoid enhancer factor (TCF/LEF) J. Biol. Chem. 2006;281:20749–20760. doi: 10.1074/jbc.M602089200. PubMed DOI

Hou P., Ma X., Zhang Q., Wu C.J., Liao W., Li J., Wang H., Zhao J., Zhou X., Guan C., et al. USP21 deubiquitinase promotes pancreas cancer cell stemness via Wnt pathway activation. Genes Dev. 2019;33:1361–1366. doi: 10.1101/gad.326314.119. PubMed DOI PMC

Han W., Lee H., Han J.K. Ubiquitin C-terminal hydrolase37 regulates Tcf7 DNA binding for the activation of Wnt signalling. Sci. Rep. 2017;7:42590. doi: 10.1038/srep42590. PubMed DOI PMC

Sun X., Cai M., Wu L., Zhen X., Chen Y., Peng J., Han S., Zhang P. Ubiquitin-specific protease 28 deubiquitinates TCF7L2 to govern the action of the Wnt signaling pathway in hepatic carcinoma. Cancer Sci. 2022;113:3463–3475. doi: 10.1111/cas.15509. PubMed DOI PMC

Liu H., Liu L., Holowatyj A., Jiang Y., Yang Z.Q. Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer. Mol. Carcinog. 2016;55:977–990. doi: 10.1002/mc.22341. PubMed DOI PMC

Huang Y., Liu Y., Yu L., Chen J., Hou J., Cui L., Ma D., Lu W. Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer. Tumor Biol. 2015;36:271–278. doi: 10.1007/s13277-014-2630-5. PubMed DOI

Zhu Q., Shen Y., Chen X., He J., Liu J., Zu X. Self-Renewal Signalling Pathway Inhibitors: Perspectives on Therapeutic Approaches for Cancer Stem Cells. OncoTargets Ther. 2020;13:525–540. doi: 10.2147/OTT.S224465. PubMed DOI PMC

Fendler A., Bauer D., Busch J., Jung K., Wulf-Goldenberg A., Kunz S., Song K., Myszczyszyn A., Elezkurtaj S., Erguen B., et al. Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients. Nat. Commun. 2020;11:929. doi: 10.1038/s41467-020-14700-7. PubMed DOI PMC

Clara J.A., Monge C., Yang Y., Takebe N. Targeting signalling pathways and the immune microenvironment of cancer stem cells—A clinical update. Nat. Rev. Clin. Oncol. 2019;17:204–232. doi: 10.1038/s41571-019-0293-2. PubMed DOI

Ladinovic D., Pinkas D., Sopin T., Raska O., Liska F., Raska I., Vacik T. Alternative isoforms of KDM2A and KDM2B lysine demethylases negatively regulate canonical Wnt signaling. PLoS ONE. 2020;15:e0236612. doi: 10.1371/journal.pone.0236612. PubMed DOI PMC

Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., Preibisch S., Rueden C., Saalfeld S., Schmid B., et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods. 2012;9:676–682. doi: 10.1038/nmeth.2019. PubMed DOI PMC

Weise A., Bruser K., Elfert S., Wallmen B., Wittel Y., Wohrle S., Hecht A. Alternative splicing of Tcf7l2 transcripts generates protein variants with differential promoter-binding and transcriptional activation properties at Wnt/β-catenin targets. Nucleic Acids Res. 2010;38:1964–1981. doi: 10.1093/nar/gkp1197. PubMed DOI PMC

Sato N., Meijer L., Skaltsounis L., Greengard P., Brivanlou A.H. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat. Med. 2004;10:55–63. doi: 10.1038/nm979. PubMed DOI

Cohen P., Goedert M. GSK3 inhibitors: Development and therapeutic potential. Nat. Rev. Drug Discov. 2004;3:479–487. doi: 10.1038/nrd1415. PubMed DOI

Li V.S., Ng S.S., Boersema P.J., Low T.Y., Karthaus W.R., Gerlach J.P., Mohammed S., Heck A.J., Maurice M.M., Mahmoudi T., et al. Wnt signaling through inhibition of β-catenin degradation in an intact Axin1 complex. Cell. 2012;149:1245–1256. doi: 10.1016/j.cell.2012.05.002. PubMed DOI

Sarikas A., Hartmann T., Pan Z.Q. The cullin protein family. Genome Biol. 2011;12:220. doi: 10.1186/gb-2011-12-4-220. PubMed DOI PMC

Pellegrino N.E., Guven A., Gray K., Shah P., Kasture G., Nastke M.D., Thakurta A., Gesta S., Vishnudas V.K., Narain N.R., et al. The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer. Int. J. Mol. Sci. 2022;23:3480. doi: 10.3390/ijms23073480. PubMed DOI PMC

Wang J., Xiang Y., Fan M., Fang S., Hua Q. The Ubiquitin-Proteasome System in Tumor Metabolism. Cancers. 2023;15:2385. doi: 10.3390/cancers15082385. PubMed DOI PMC

Graham T.A., Ferkey D.M., Mao F., Kimelman D., Xu W. Tcf4 can specifically recognize β-catenin using alternative conformations. Nat. Struct. Biol. 2001;8:1048–1052. doi: 10.1038/nsb718. PubMed DOI

Zuo Y., Zhan L., Wen H., Xue J., Tan Y., Sun W., Xu E. Stabilization of nuclear β-catenin by inhibiting KDM2A mediates cerebral ischemic tolerance. FASEB J. 2023;37:e22796. doi: 10.1096/fj.202201657. PubMed DOI

Hwang S.G., Yu S.S., Ryu J.H., Jeon H.B., Yoo Y.J., Eom S.H., Chun J.S. Regulation of beta-catenin signaling and maintenance of chondrocyte differentiation by ubiquitin-independent proteasomal degradation of α-catenin. J. Biol. Chem. 2005;280:12758–12765. doi: 10.1074/jbc.M413367200. PubMed DOI

Schwechheimer C. NEDD8-its role in the regulation of Cullin-RING ligases. Curr. Opin. Plant Biol. 2018;45:112–119. doi: 10.1016/j.pbi.2018.05.017. PubMed DOI

Wang B., Wang T., Zhu H., Yan R., Li X., Zhang C., Tao W., Ke X., Hao P., Qu Y. Neddylation is essential for β-catenin degradation in Wnt signaling pathway. Cell Rep. 2022;38:110538. doi: 10.1016/j.celrep.2022.110538. PubMed DOI

Zhang L., Jing H., Li H., Chen W., Luo B., Zhang H., Dong Z., Li L., Su H., Xiong W.C., et al. Neddylation is critical to cortical development by regulating Wnt/β-catenin signaling. Proc. Natl. Acad. Sci. USA. 2020;117:26448–26459. doi: 10.1073/pnas.2005395117. PubMed DOI PMC

Yang Y., Li S., Li B., Li Y., Xia K., Aman S., Yang Y., Ahmad B., Zhao B., Wu H. FBXL10 promotes ERRα protein stability and proliferation of breast cancer cells by enhancing the mono-ubiquitylation of ERRα. Cancer Lett. 2021;502:108–119. doi: 10.1016/j.canlet.2021.01.007. PubMed DOI

Yuan T.Z., Lin H.Y., Kuei C.H., Lin C.H., Lee H.H., Lee H.L., Lu H.W., Su C.Y., Chiu H.W., Lin Y.F. NEDD8 promotes radioresistance via triggering autophagy formation and serves as a novel prognostic marker in oral squamous cell carcinoma. Cancer Cell Int. 2023;23:41. doi: 10.1186/s12935-023-02883-0. PubMed DOI PMC

Zhou L., Lin X., Zhu J., Zhang L., Chen S., Yang H., Jia L., Chen B. NEDD8-conjugating enzyme E2s: Critical targets for cancer therapy. Cell Death Discov. 2023;9:23. doi: 10.1038/s41420-023-01337-w. PubMed DOI PMC